Opportunities

Revolutionising automated digital epilepsy diagnosis quickly and accurately. Created by an expert in the mathematical modelling of epilepsy. Tried and tested by neurologists.

Neuronostics is targeting the $180bn epilepsy cost and treatment market, with long-term expansion into the $2tr neurological illness cost market.

Key distribution partner Stratus (the leading US EEG services provider) offers a turnkey route to market and removes the need for Neuronostics to have a US salesforce by providing nationwide coverage via 600+ hospital systems to 30,000 annual tests. BioEP is embedded in their platform and already being used in the UK.

Early sales generated across the UK via the NHS – ongoing service evaluations and clinical trials with 20+ NHS Trusts. The focus is on the UK through 2026 with US expansion in 2027.

Neuronostics has raised c£4.9m in equity and [c£##] grant funding to date, which has been used to build the product, bring it to market and secure validation from medical professionals and customers.

The Company is currently raising up to £3.5m (EIS qualifying and KIC status expected), of which £3m has already been invested by VCs (including two specialist MedTech funds) at a £6.4m pre-money valuation.

Your VC has secured an allocation of up to £264k of the round for its investors, benefiting from the same share price as at the beginning of the round before £3m had been raised.